Key Points
-
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of several malignancies, converting lethal diseases into manageable, if not curable, chronic diseases. This makes it essential to limit toxicities of these agents.
-
The goal of tumour-cell killing by TKIs must be balanced against cardiotoxicity, because in some instances tumour cell death and preservation of cardiomyocyte health may be mutually exclusive.
-
Cardiomyocytes are contractile and have an extremely high demand for ATP. As a result, they might be particularly susceptible to agents that perturb mitochondrial function, either as a primary or secondary effect. Therefore, alterations in mitochondrial function could have a role in the cardiotoxicities of some currently approved agents.
-
Very few clinical trials have examined cardiotoxicities of TKIs in a prospective fashion with predefined cardiac endpoints, including left ventricular function. Therefore, there is a wide gap in our knowledge regarding the types of, and risk of, cardiotoxicity for most of these agents.
-
Some current kinase targets in cancer are not expressed in cardiomyocytes and therefore have little or no direct role in cardiomyocyte survival. However, the current generation of TKIs is inherently non-selective, and the purposeful design of multi-targeted TKIs might allow a single agent to be more effective, and to be used in more types of cancer, but with this comes an increased risk of cardiotoxicity. In some cases this will probably be due to inhibition of 'bystander' targets that are not essential for the killing of tumour cells but that are involved in cardiomyocyte survival.
-
Identification of the kinase that, when inhibited, is responsible for cardiotoxicity of an agent is important for future drug design, which should avoid these kinases where possible. Thus, greater selectivity of individual agents may require the use of more agents to treat a particular cancer, but cardiotoxicity as an 'off-target' effect should be minimized.
Abstract
Cancer therapy has progressed remarkably in recent years. In no area has this been more apparent than in the development of 'targeted therapies', particularly those using drugs that inhibit the activity of certain tyrosine kinases, activating mutations or amplifications of which are causal, or strongly contributory, to tumorigenesis. However, some of these therapies have been associated with toxicity to the heart. Here we summarize what is known about the cardiotoxicity of cancer drugs that target tyrosine kinases. We focus on basic mechanisms through which interruption of specific signalling pathways leads to cardiomyocyte dysfunction and/or death, and contrast this with therapeutic responses in cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653 (2005).
Oeffinger, K. C. et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572–1580 (2006). This work identifies the increased risk of cardiovascular toxicity in adults who have survived a childhood cancer, highlighting the importance of minimizing cardiovascular complications of cancer therapies.
Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).
Kerkela, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med. 12, 908–916 (2006). This work explores the mechanisms of cardiomyocyte toxicity associated with imatinib and identifies signalling pathways mediating the toxicity.
Motzer, R. J. et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Chakko, S. et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am. J. Med. 90, 353–359 (1991).
Stevenson, L. W. & Perloff, J. K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. J. Am. Med. Assoc. 261, 884–888 (1989).
Druker, B. J. et al. Efficacy and safety of a specific inhi-bitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
Slaman, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Park, Y. H. et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 243, 16–22 (2006).
Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329–336 (2005). These researchers use a new technology to raise concerns about the non-selectivity of TKIs, particularly multi-targeted TKIs.
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Seidman, A. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20, 1215–1221 (2002).
Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
Gonzalez-Angulo, A. M., Hortobagyi, G. N. & Esteva, F. J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11, 857–867 (2006).
Tan-Chiu, E. et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811–7819 (2005).
Bengala, C. et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br. J. Cancer 94, 1016–1020 (2006).
Ewer, M. S. et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23, 7820–7826 (2005).
Perez, E. A. & Rodeheffer, R. Clinical cardiac tolerability of trastuzumab. J. Clin. Oncol. 22, 322–329 (2004).
Elliott, P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol. 33, S2–S7 (2006).
Zhao, Y. Y. et al. Neuregulins promote survival and growth of cardiac myocytes. J. Biol. Chem. 273, 10261–10269 (1998).
Kuramochi, Y., Guo, X. & Sawyer, D. B. Neuregulin activates ERBB2-dependent Src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J. Mol. Cell. Cardiol. 41, 228–235 (2006).
Lee, K. F. et al. Requirement for neuregulin receptor ERBB2 in neural and cardiac development. Nature 378, 394–398 (1995).
Gassmann, M. et al. Abberant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature 378, 390–394 (1995).
Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386–390 (1995).
Crone, S. A. et al. ERBB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8, 459–465 (2002). References 30 and 31 describe the cardiac phenotype of knockout Erbb2 mice, thereby defining ERBB2 as an essential survival factor in the heart.
Ozcelik, C. et al. Conditional mutation of the ErbB2 (Her2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 8880–8885 (2002).
Burris, H. A. et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305–5313 (2005).
Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
Sliwkowski, M. X. et al. Nonclincial studies addressing the mechanism of action of trastuzumab. Semin. Oncol. 26, 60–70 (1999).
Gordon, M. S. et al. Clinical activity of pertuzumab, a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24, 4324–4332 (2006).
Menendez, J. A., Mehmi, I. & Lupu, R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J. Clin. Oncol. 24, 3735–3746 (2006).
Grazette, L. et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44, 2231–2238 (2004). This work identifies a possible mechanism by which trastuzumab leads to cardiac dysfunction without apoptosis, and might provide a mechanism to understand the reversibility of this cardiotoxicity.
Potts, M. B., Vaughan, A. E., McDonough, H., Patterson, C. & Deshmukh, M. Reduced Apaf-1 levels in cardiomyocytes engage a strict regulation of apoptosis by endogenous XIAP. J. Cell Biol. 171, 925–930 (2005). This work identifies mechanisms by which cardiomyocytes may be uniquely resistant to apoptosis induced by the mitochondrial pathway.
Xia, W. et al. Combining lapatinib (GW572016), a small molecule inhibitor of ERBB1 and ERBB2 tyrosine kinses, with therapeutic anti-ERBB2 anti-bodies enhances apoptosis of ERBB2-overexpressing breast cancer cells. Oncogene 24, 6213–6221 (2005).
O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nature Rev. Drug Discov. 5, 717–718 (2006).
Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
Force, T. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Med. 13, 15–16 (2007).
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y. C. & Beer, T. M. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J. Clin. Oncol. 22, 3485–3490 (2004).
Scharf, O. & Colevas, D. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J. Clin. Oncol. 24, 3933–3938 (2006).
Dyck, J. R. B. & Lopaschuk, G. D. AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol. 574, 95–112 (2006).
Yuan, J., Lipinski, M. & Degterev, A. Diversity in the mechanisms of neuronal cell death. Neuron 15, 961–973 (2003).
Ankarcrona, M. et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15, 961–973 (1995).
Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001).
Li, B. et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase Cδ. Genes Dev. 18, 1824–1837 (2004).
Cao, C., Leng, Y., Huang, W., Liu, X. & Kufe, D. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J. Biol. Chem. 278, 39609–39614 (2003).
Cao, C., Leng, Y. & Kufe, D. Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J. Biol. Chem. 278, 29667–29675 (2003).
Cao, C. et al. Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress. Oncogene 24, 2433–2440 (2005).
Bristol-Myers Squibb. Sprycel (dasatinib) Prescribing Information [online] (2006).
Zhang, K. & Kaufman, R. J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66, S102–S109 (2006).
Zhang, K. & Kaufman, R. J. Signaling the unfolded protein response from the endoplasmic reticulum. J. Biol. Chem. 279, 25935–25938 (2004).
Ron, D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110, 1383–1388 (2002).
Steinberg, S. F. Distinctive activation mechanisms and functions for protein kinase C δ. Biochem. J. 384, 449–459 (2004).
Ito, Y. et al. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol. Cell. Biol. 21, 6233–6242 (2001).
Sun, X., Wu, F., Datta, R., Kharbanda, S. & Kufe, D. Interaction between protein kinase C δ and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J. Biol. Chem. 275, 7470–7473 (2000).
Pattacini, L. et al. Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 BCR–ABL tyrosine kinase. Leuk. Res. 28, 191–202 (2004).
Schermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811–2821 (2005).
Abdollahi, A. et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925–935 (2005).
Wang, C.-H. et al. Stem cell factor deficiency is vasculoprotective. Circ. Res. 99, 617–625 (2006).
Branca, M. A. Multi-kinase inhibitors create buzz at ASCO. Nature Biotech. 23, 639 (2005).
Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338 (2006).
Pfizer . Sutent (sunitinib) Prescribing Information [online](2007).
Desai, J. et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 145, 660–664 (2006).
Hsieh, P. C., MacGillvray, C., Gannon, J., Cruz, F. U. & Lee, R. T. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114, 637–644 (2006).
Terai, K. et al. AMP-activated protein kianse protects cardiomyocytes against hypoxic injury through attentuation of endoplasmic reticulum stress. Mol. Cell. Biol. 25, 9554–9575 (2005).
Bayer Pharmaceuticals. Nexavar (sorafenib) Prescribing Information [online](2006).
Kyriakis, J. M., Force, T. L., Rapp, U. R., Bonventre, J. V. & Avruch, J. Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase kinase. J. Biol. Chem. 268, 16009–16019 (1993).
Chen, J., Fujii, K., Zhang, L., Roberts, T. & Fu, H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulated kinase 1 through a MEK–ERK-independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783–7788 (2001).
O'Neill, E., Rushworth, L., Baccarani, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267–2270 (2004).
Muslin, A. J. Role of Raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc. Med. 15, 225–229 (2005).
Yamaguchi, O. et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc. Natl Acad. Sci. USA 100, 15883–15888 (2003).
O'Neill, E. & Kolch, W. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippl. Cell Cycle 4, 365–367 (2005).
Yamaguchi, O. et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 114, 937–943 (2004). References 78 and 79 describe essential functions of RAF1 in the heart, raising concerns about long-term use of RAF1 inhibitors.
Harris, I. S. et al. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110, 718–723 (2004).
Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transtion to heart failure. J. Clin. Invest. 115, 2108–2118 (2005). References 80 and 81 highlight the critical role of angiogenesis in the adaptation to pressure loads on the heart.
Izumiya, Y. et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47, 887–893 (2006).
Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).
Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
Negoro, S. et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc. Res. 47, 797–805 (2000).
Hilfiker-Kleiner, D., Limbourg, A. & Drexler, H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc. Med. 15, 152–157 (2005).
Hilfiker-Kleiner, D. et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95, 187–195 (2004).
Kunisada, K. et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl Acad. Sci. USA 97, 315–319 (2000).
Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669–3676 (2004).
Ayach, B. B. et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc. Natl Acad. Sci. USA 103, 2304–2309 (2006). References 89 and 90 illustrate potential concerns about the effect of long-term inhibition of KIT on cardiac function after a heart attack.
Fazel, S. et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116, 1865–1877 (2006).
van Heeckeren, W. J. et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol. 24, 1485–1488 (2006).
Van Etten, R. A. & Shannon, K. M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547–552 (2004).
Gilliland, D. G. & Tallman, M. S. Focus on acute leukemias. Cancer Cell 1, 417–420 (2002).
Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201–1214 (2003).
James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
Golub, T. R., Barker, G. F., Lovett, M. & Gilliland, D. G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77, 307–316 (1994).
Macdonald, D., Reiter, A. & Cross, N. C. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 107, 101–107 (2002).
Lacouture, M. E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev. Cancer 6, 803–812 (2006).
Cwynarski, K. et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18, 1332–1339 (2004).
Dietz, A. B. et al. Imatinib meylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104, 1094–1099 (2004).
Seggewiss, R. et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependen manner. Blood 105, 2473–2479 (2005).
Zipfel, P. A., Zhang, W., Quiroz, M. & Pendergast, A. M. Requirement for Abl kinases in T cell receptor signaling. Curr. Biol. 14, 1222–1231 (2004).
Gao, H. et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19, 1905–1911 (2005).
Dewar, A. L., Doherty, K. V., Hughes, T. P. & Lyons, A. B. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol. Cell Biol. 83, 48–56 (2005).
Cebo, C. et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J. Immunol. 176, 864–872 (2006).
Wang, H. et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105, 1135–1143 (2005).
Lavrik, I. N., Golks, A. & Krammer, P. H. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 115, 2665–2672 (2005).
Reed, J. C. Apoptosis-based therapies. Nature Rev. Drug Discov. 1, 111–121 (2002).
Foo, R. S., Mani, K. & Kitsis, R. N. Death begets failure in the heart. J. Clin. Invest. 115, 565–571 (2005).
Acknowledgements
We thank R. Kerkela, K. Woulfe, M.-H. Chen and M. Rupnick for their contributions to this work. The work was supported by grants from the National Heart Lung and Blood Institute (to T.F.) and a SCOR (Specialized Centers of Research) grant from the Leukemia and Lymphoma Society (to R.A.V.). We want to point out that the highlighted references focus predominantly on mechanisms of cardiotoxicity and, therefore, there are many papers describing major advances in oncology that are not highlighted.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Thomas Force is a consultant for Novartis Pharmaceuticals, Inc. and he is on the Speakers' Bureau for Merck & Co. Inc.
Related links
Glossary
- Cardiomyocytes
-
The contractile cells of the heart that generate force. These cells are terminally differentiated and so cardiomyocytes lost through injury can only be replaced by differentiation of progenitor cells.
- Congestive heart failure
-
(CHF). A medical condition in which the contractile function of the heart muscle declines, leading to an enlarged heart with dilated chambers, impaired pumping (left ventricular dysfunction), fluid congestion in the lungs, fluid collection in the legs (oedema) and decreased perfusion of tissues. Patients may have low blood pressure, shortness of breath with exercise or when lying flat, and decreased kidney function.
- Grades of CHF
-
The severity of CHF is graded on a clinical scale from I to IV. This scale was established by the New York Heart Association (NYHA). NYHA class I patients are asymptomatic, even with exertion, and class IV patients have significant symptoms even at rest.
- Gastrointestinal stromal tumour
-
(GIST). A rare cancer of the upper gastrointestinal tract (stomach and duodenum) arising from cells of neuroendocrine origin. Most GIST tumours contain activating mutations in KIT or PDGFRα, and so respond to imatinib and sunitinib therapy.
- Left ventricular ejection fraction
-
(LVEF). A measure of the pumping ability of the heart, defined as the percentage change in the volume of the left ventricle (the main chamber of the heart that pumps blood coming from the lungs out to the body) when the ventricle contracts. A normal LVEF is 50–70%. EFs below 50% indicate LV dysfunction.
- Antibody-dependent cell-mediated cytotoxicity
-
(ADCC). A mechanism of cell death mediated by antibody binding to a target cell, followed by recognition through Fc receptors on cytotoxic T-lymphocytes or natural killer cells, leading to target cell killing.
- Dilated cardiomyopathy
-
A condition characterized by both dilation of the heart and reduced contractile function, often leading to CHF.
- Pressure overload stress
-
A technique used in experimental animals that leads to a marked and sudden increase in blood pressure in the heart, which is typically induced by partially occluding the aorta with a suture.
- Mitochondrial permeability transition pore
-
A mitochondrial pore that, when opened by pathological stresses, leads to collapse of the mitochondrial membrane potential, disruption of energy production, and mitochondrial swelling and rupture with release of cytochrome c.
- Neointima
-
The intima is the layer of the arterial wall immediately adjacent to endothelial cells. After catheter intervention, a hypercellular intima can re-form, leading to re-obstruction of the vessel.
Rights and permissions
About this article
Cite this article
Force, T., Krause, D. & Van Etten, R. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7, 332–344 (2007). https://doi.org/10.1038/nrc2106
Issue Date:
DOI: https://doi.org/10.1038/nrc2106
This article is cited by
-
The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice
Apoptosis (2024)
-
Evaluating the efficacy and cardiotoxicity of EGFR-TKI AC0010 with a novel multifunctional biosensor
Microsystems & Nanoengineering (2023)
-
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
Signal Transduction and Targeted Therapy (2023)
-
Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma
Science China Life Sciences (2023)
-
The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity
Journal of Cardiovascular Translational Research (2023)